BBOT News

BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference

BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)

BBOT to Participate in Upcoming December Investor Healthcare Conferences

BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

BBOT to Participate in the Jefferies Global Healthcare Conference in London

BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics